Loading...
01/10 16:05
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presented mixed signals: while there are positive elements like new product launches and a share repurchase program, there are also concerns such as reduced free cash flow guidance, tariff impacts, and competitive pressures. The Q&A section revealed management's uncertainty about tariffs and their impact, which could weigh on investor sentiment. Overall, the combination of positive and negative factors suggests a neutral outlook for the stock price over the next two weeks.
Net Sales $1,909,000,000 (up 1.1% reported, up 2.3% constant currency) due to growth in U.S. hips and SET despite one less selling day.
Adjusted EPS $1.81 (down from $1.94 year-over-year) due to higher COGS, upfront investments for new products, and higher interest expense.
GAAP EPS $0.91 (up from $0.84 year-over-year) driven by higher sales and lower restructuring charges.
Free Cash Flow $279,000,000 (up from previous year) reflecting strong cash generation and working capital initiatives.
Adjusted Gross Margin 71.5% (down from previous year) in line with expectations.
Adjusted Operating Margin 26.2% (lower than prior year) due to higher costs and investments.
Days on Hand (DOH) Approximately 370 days (reduced from over 400 days early in 2024) due to inventory reduction initiatives.
Tariff Impact $60,000,000 to $80,000,000 headwind expected in 2025, with mitigation efforts in place.
Cash and Cash Equivalents Approximately $1,400,000,000, including proceeds from debt issuance for Paragon 28 acquisition.
2025 Free Cash Flow Guidance $750,000,000 to $850,000,000 (down from previous guidance of $1,100,000,000 to $1,200,000,000) due to tariff-related headwinds and one-time costs from Paragon 28 acquisition.
New Product Launches: The Z1 hip stem, HEMR surgical impactor, and Orthogrip AI-driven surgical guidance system are driving growth in U.S. hips, with nearly 4% growth in the first quarter.
Cementless Knee Products: The Persona Oceutide cementless knee and Oxford partial cementless knee are expected to drive growth, with over 25% penetration in the U.S.
Iodine Surface Treated Implants: The first iodine surface treated hip stem will launch in Japan later this year, aimed at preventing infections.
Market Expansion: The Paragon 28 acquisition is expected to contribute 270 basis points to sales growth in 2025, enhancing Zimmer Biomet's market position.
U.S. Market Growth: U.S. sales grew 1.3%, with significant contributions from hips and SET, indicating a strong market presence.
Operational Efficiencies: Days on hand (DOH) reduced from over 400 to approximately 370, improving inventory management and cash flow.
Sales Channel Optimization: Changes in U.S. sales channels are being made to enhance performance, including new leadership and specialization of sales teams.
Strategic Priorities: Focus on people and culture, operational excellence, and innovation to drive growth and improve market positioning.
M&A Strategy: Zimmer Biomet is open to further acquisitions that align with strategic goals, particularly in the ASC and SET markets.
Tariffs Impact: Anticipated headwind of $60 million to $80 million on operating profit in 2025 due to tariffs, with the majority of the impact expected in the second half of the year.
Foreign Exchange Fluctuations: Weakening of the U.S. Dollar expected to offset some tariff impacts, with a potential flat to 50 basis point tailwind in 2025.
Supply Chain Challenges: Ongoing adjustments in sourcing strategies to mitigate tariff impacts, including dual sourcing and optimizing country of origin.
Competitive Pressures: Need to improve U.S. knee performance, which grew only 0.2% in the quarter, indicating challenges in maintaining market share against competitors.
Economic Factors: Shifts in discretionary spending and operational strategies are impacting revenue growth expectations.
Integration Risks: Potential challenges in integrating the Paragon 28 acquisition, although initial integration has been reported as successful.
Operational Efficiency: Focus on reducing inventory days and improving cash flow generation, with a target to lower days on hand from 370 to a much lower number in future quarters.
Strategic Priorities: Zimmer Biomet's strategic priorities include focusing on people and culture, operational excellence, and innovation and diversification.
Acquisition of Paragon 28: The acquisition of Paragon 28 was completed on April 21, 2025, and is expected to contribute approximately 270 basis points to sales growth in 2025.
Innovation Focus: The company is focusing on addressing unmet needs in musculoskeletal health, including awareness, safety, efficiency, and outcomes.
Sales Channel Optimization: Changes are being made to optimize the U.S. sales channel, including specialization of the sales team and expanding product offerings.
2025 Revenue Growth Guidance: Zimmer Biomet maintains its full-year organic constant currency revenue growth expectations of 3% to 5%, excluding the impact of the Paragon 28 acquisition.
Adjusted EPS Guidance: The adjusted EPS guidance for 2025 has been updated to $7.90 to $8.10, down from the previous range of $8.15 to $8.35.
Free Cash Flow Guidance: Free cash flow for 2025 is projected to be between $750 million and $850 million, down from previous expectations of $1.1 billion to $1.2 billion.
Tariff Impact: The anticipated headwind from tariffs in 2025 is estimated to be between $60 million and $80 million, primarily affecting the second half of the year.
Operating Margin Guidance: Full-year adjusted operating margins are expected to decline by approximately 100 to 150 basis points compared to 2024.
Share Repurchase Program: Executed $230,000,000 in share repurchases during the quarter.
The earnings call summary presents mixed signals. While there are positive elements like raised EPS guidance and new product launches, concerns arise from declining operating margins and uncertainties in international markets. The Q&A reveals cautious management responses, a choppy U.S. revision market, and market share loss in U.S. knees. Although optimistic guidance and potential premium pricing for iodine-coated implants are positive, the lack of specific guidance for 2026 and cautious capital allocation strategy tempers expectations. Overall, the sentiment is neutral, with potential upside from innovation and strategic acquisitions.
The earnings call reveals mixed signals. While there are positive aspects like the acquisition of Paragon 28, strong July performance, and optimism about Monogram's technology, there are concerns about reduced EPS guidance, tariff impacts, and declining operating margins. The Q&A section shows confidence in growth but lacks specific guidance for 2026. The neutral sentiment reflects these balanced positive and negative factors.
The earnings call reflects several concerns: ongoing operational challenges, economic factors affecting revenue growth, and a significant tariff impact on profits. Despite new product launches and share repurchases, the guidance for free cash flow and EPS has been lowered. The Q&A section highlights uncertainties regarding tariff mitigation and sales force reorganization. These factors, combined with modest acquisition dilution and a cautious market outlook, suggest a likely negative stock reaction in the near term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
